GCTK: Glucotrack's Lōkahi ai2 Futures Lab identifies 45+ drug opportunities, expands to 12 university partners

AI Summary

Glucotrack (via subsidiary Lōkahi Therapeutics) said its ai2 Futures Lab identified more than 45 therapeutic opportunities on roughly a $33,000 budget in year one, advanced five into active company discussions, and flagged assets that represent over $500M of prior industry investment including candidates with human clinical data and positive efficacy signals. The program is expanding from 6 to 12 university partners for 2026–27 (100% retention), positioning Lōkahi as a low‐cost, distributed asset-origination engine to source overlooked late-stage assets for potential acquisition, partnering, or monetization, though identified opportunities still require further due diligence and capital to realize value.

Positives

Identified 45+ therapeutic opportunities on approximately $33,000 budget during first year
Advanced five opportunities into active company discussions; flagged assets include human clinical data and positive efficacy signals and represent >$500M prior industry investment
Expanded university collaborations from 6 to 12 for 2026–27 and retained all inaugural partners

Negatives

Identified assets are opportunities under evaluation, not completed acquisitions or guaranteed value realizations
Realization of value depends on further due diligence, partnering or capital deployment
Program outputs are sourced via student-led engagements and require Lōkahi leadership review before company action